Illustrative image.
LEMTRADA
Alemtuzumab
$13350.00
12mg/1.2ml · 1 vial
BrandBranded medicine· By Sanofi-Aventis
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningAutoimmunity, infusion reactions, stroke, and malignancies
LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts before starting treatment and then at monthly intervals until 48 months after the last dose of LEMTRADA.
LEMTRADA causes serious and life-threatening infusion reactions. LEMTRADA must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reactions. Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period.
Serious and life-threatening stroke (including ischemic and hemorrhagic stroke) has been reported within 3 days of LEMTRADA administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.
LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams.
Because of the risk of autoimmunity, infusion reactions, and malignancies, LEMTRADA is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the LEMTRADA REMS program.
LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts monthly until 48 months after the last dose.
Serious and life-threatening stroke has been reported within 3 days of LEMTRADA administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.
LEMTRADA is available only through a restricted distribution program.
About LEMTRADA
Overview
LEMTRADA (alemtuzumab) is a prescription monoclonal antibody medicine given by intravenous infusion to treat relapsing forms of multiple sclerosis in adults, including relapsing-remitting disease and active secondary progressive disease. Because of its safety profile, it is generally reserved for people who have not responded adequately to at least two other MS medicines. It is not recommended for clinically isolated syndrome. Its exact action in MS is unknown, but it is thought to work by binding to CD52 on immune cells, leading to the destruction of T and B cells.
What it treats
- Relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting MS and active secondary progressive MS. Because of its safety profile, LEMTRADA is generally reserved for patients who have had an inadequate response to two or more MS medicines. It is not recommended for clinically isolated syndrome (CIS).
Safety information
Side effects
Common side effects include rash, headache, fever, nose and throat inflammation, nausea, urinary tract infection, tiredness, difficulty sleeping, upper respiratory tract infection, herpes infection, hives, itching, thyroid disorders, fungal infection, joint pain, pain in the arms or legs, back pain, diarrhoea, sinusitis, throat pain, tingling or prickling sensations, dizziness, abdominal pain, flushing and vomiting. Serious side effects include infusion reactions, stroke, tears in arteries supplying the head and neck, cancers, and infections, including progressive multifocal leukoencephalopathy (PML). LEMTRADA can also cause autoimmune conditions affecting the blood, kidneys, thyroid, liver or brain. These include low platelet counts, other low blood cell counts, kidney disease, autoimmune hepatitis, autoimmune encephalitis and acquired haemophilia A. Other serious reactions include thrombotic thrombocytopenic purpura (TTP), severe inflammatory conditions such as haemophagocytic lymphohistiocytosis and adult-onset Still’s disease, immune-related inflammation of the colon, gallbladder inflammation without gallstones, and lung inflammation. Contact a doctor promptly if you develop symptoms suggesting a serious reaction. Symptoms specifically highlighted in the label include unexplained or extensive bruising, bleeding under the skin, blood in the urine, nosebleeds or other bleeding; new memory problems, changes in mental state, psychiatric symptoms, neurological changes or seizures; and new or persistent diarrhoea or other digestive symptoms. Suspected TTP or widespread inflammation requires immediate medical evaluation. Regular monitoring is required to detect some serious reactions. Blood counts and kidney tests are needed before treatment and monthly until 48 months after the last infusion. Thyroid tests are needed before treatment and every three months until 48 months after the last infusion.
FDA boxed warning
Autoimmunity, infusion reactions, stroke, and malignancies
LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts before starting treatment and then at monthly intervals until 48 months after the last dose of LEMTRADA.
LEMTRADA causes serious and life-threatening infusion reactions. LEMTRADA must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reactions. Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period.
Serious and life-threatening stroke (including ischemic and hemorrhagic stroke) has been reported within 3 days of LEMTRADA administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.
LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams.
Because of the risk of autoimmunity, infusion reactions, and malignancies, LEMTRADA is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the LEMTRADA REMS program.
LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts monthly until 48 months after the last dose.
Serious and life-threatening stroke has been reported within 3 days of LEMTRADA administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.
LEMTRADA is available only through a restricted distribution program.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not receive LEMTRADA if you are allergic to alemtuzumab or any of its ingredients, have previously had an anaphylactic reaction to them, have HIV infection, or have an active infection. LEMTRADA causes prolonged reductions in CD4+ lymphocytes, a type of immune cell. Important risks requiring monitoring include low platelet or other blood cell counts, kidney disease, thyroid disorders, autoimmune liver inflammation, serious inflammatory conditions, blood-clotting and bleeding disorders, autoimmune brain inflammation, and immune-related inflammation of the colon. Blood counts and kidney tests are required before treatment and monthly until 48 months after the last infusion. Thyroid tests are required before treatment and every three months until 48 months after the last infusion. Seek prompt medical assessment for unusual bruising or bleeding, new memory problems, confusion, psychiatric symptoms, seizures, or new or persistent diarrhoea or other digestive symptoms. Treatment must be withheld at the first sign or symptom suggesting progressive multifocal leukoencephalopathy (PML), a serious brain condition. Do not receive live viral vaccines after a course of LEMTRADA. LEMTRADA may harm an unborn baby. Women who could become pregnant should use effective contraception during treatment and for four months after a treatment course.
Using LEMTRADA
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label LEMTRADA (ALEMTUZUMAB) INJECTION, SOLUTION, CONCENTRATE [GENZYME CORPORATION] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Tecfidera
Dimethyl Fumarate
Capsules · from 14 per pack
Also for multiple sclerosis
Brand and generic from $303.00
Kesimpta
Ofatumumab
By Novartis
Pre-Filled Syringe · from 1 per pack
Also for multiple sclerosis
Brand $2,675.00
Ocrevus
Ocrelizumab
By Roche
Vial · from 1 per pack
Also for multiple sclerosis
Brand $9,000.00
Mayzent
Siponimod
By Novartis
Tablets · from 12 per pack
Also for multiple sclerosis
Brand from $430.00